Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Ariel Finkelstein The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

Sabina Izraelov The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

Arie Roth The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

Sigal Ben-Shmuel The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

Gad Keren The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

Hylton Miller The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

Jacob George The Department of Cardiology Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University Israel

show all

Abstract

Inhibitors of the IIB-IIIA integrin are widely used to prevent stent thrombosis. Abciximab has been shown to attenuate the inflammatory response in patients undergoing PCI. Herein, we tested the effect of eptifibatide infused during PCI on peripheral lymphocyte activation and CRP levels before, and one month after the procedure showing no noticeable effect. These results may explain the differences in clinical outcome following PCI by use of different IIB-IIIA agents. (Int J Cardiovasc Intervent 2004; 6: 107-109)

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Information for

Open access

Opportunities

Help and information

Eptifibatide does not influence lymphocyte activation and CRP levels in patients with undergoing coronary angioplasty

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature